This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants (NCT04255862), a randomized phase 1 study. The primary outcome is Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04255862 |
| Phase | Phase 1 |
| Condition | Healthy Study Participants |
| Allocation | Randomized |
| Design model | Single Group |
| Masking | None (open label) |
| Enrollment | 71 |
| Arms in the primary outcome | 4 |
| Lead sponsor | UCB Biopharma SRL |
| Results posted | Yes |
2. Clinical Question
Population
Healthy study participants. The registry record lists 71 enrolled participants. The primary pharmacokinetic analysis used a per-protocol set, defined as participants without important protocol deviations affecting pharmacokinetic variables and with enough samples to determine at least one pharmacokinetic parameter.
Intervention
Bimekizumab given subcutaneously as a single dose in either a 2 mL safety-syringe presentation or a 2 mL auto-injector presentation. These are the test presentations in the respective comparisons.
Comparator
For each presentation type, the comparator was bimekizumab administered as two 1 mL injections: a safety-syringe presentation or an auto-injector presentation. The comparisons therefore concern volume and presentation within each device type, not bimekizumab versus a different drug.
Primary question
How do the plasma exposure profiles, summarized by area under the concentration-time curve from time zero to infinity, compare between the 2 mL and two-injection 1 mL presentations? The posted results give geometric mean ratios and 90% confidence intervals for the safety-syringe and auto-injector comparisons.
The clinical question is pharmacokinetic: whether exposure after the single-dose presentations is sufficiently similar under the study’s bioequivalence assessment. It is not a study of clinical benefit or treatment of a health condition. The registry record describes an open-label, randomized, parallel-group study in healthy participants. It lists four arms, allowing the 2 mL and two 1 mL presentations to be compared separately for the safety syringe and auto-injector. Whether the posted intervals satisfy the study’s prespecified bioequivalence criteria cannot be determined from the record because the acceptance margins and detailed decision rule are not reported in the registry record.
3. Trial Design
The registry record describes a phase 1, randomized, open-label, single-center, parallel-group, single-dose study. Its purpose was to compare bimekizumab pharmacokinetics following subcutaneous administration as 1x2 mL versus 2x1 mL, using either a safety-syringe or auto-injector presentation. The record lists 71 participants enrolled and identifies the study status as terminated. The reason for termination is not reported in the registry record.
There were four randomized arms. One safety-syringe group received the 2 mL test presentation, and its reference group received the 1 mL presentation as two injections. The other pair used the auto-injector: one group received the 2 mL test presentation, while its reference group received the 1 mL presentation as two injections. Thus, the posted pharmacokinetic comparisons are within device type. The record does not describe a comparison between the safety syringe and auto-injector as the primary question.
The posted AUC arm summaries include 18 participants for the safety-syringe 2 mL group, 18 for the safety-syringe reference group, 17 for the auto-injector 2 mL group, and 18 for the auto-injector reference group. These counts describe the posted endpoint summaries and should not be assumed to represent every analysis population. The record defines the primary pharmacokinetic per-protocol set but does not report the full flow of participants from enrollment to each analysis set.
Randomization details, allocation ratio, the reasons for termination, and the detailed protocol are not reported in the registry record. Although the study is described as open-label, the record does not explain how that status affected measurement or conduct. No conclusion about trial completion or the sponsor’s reasons for stopping should be inferred from the status alone.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: Participant Flow refers to the Randomized Set (RS) which consisted of all randomized study participants.
Overall Study
| Stage | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| STARTED | 18 | 18 | 17 | 18 |
| COMPLETED | 18 | 18 | 17 | 18 |
| NOT COMPLETED | 0 | 0 | 0 | 0 |
Analysis population for the primary outcome, as defined in the registry: The Pharmacokinetic Per-Protocol Set (PK-PPS) was a subset of the FAS, consisting of those study participants who had no important protocol deviations affecting the PK variables and for whom a sufficient number of samples were available to determine at least 1 PK parameter.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
Population: Baseline Characteristics refer to the Full Analysis Set (FAS) which consisted of all randomized study participants who received full or partial investigational medicinal product (IMP) according to the treatment the study participants actually received.
| Characteristic | Unit | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) | Total |
|---|---|---|---|---|---|---|
| Participants analysed | 18 | 18 | 17 | 18 | 71 | |
| Age, Categorical: <=18 years | Participants | 0 | 0 | 0 | 0 | 0 |
| Age, Categorical: Between 18 and 65 years | Participants | 17 | 17 | 16 | 16 | 66 |
| Age, Categorical: >=65 years | Participants | 1 | 1 | 1 | 2 | 5 |
| Age, Continuous | years | 52.6 (SD 12.8) | 51.1 (SD 15.8) | 46.8 (SD 15.7) | 46.7 (SD 15.7) | 49.3 (SD 15.0) |
| Sex: Female, Male: Female | Participants | 12 | 13 | 13 | 13 | 51 |
| Sex: Female, Male: Male | Participants | 6 | 5 | 4 | 5 | 20 |
| Race/Ethnicity, Customized: White | Participants | 17 | 17 | 17 | 18 | 69 |
| Race/Ethnicity, Customized: Other/Black | Participants | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized: Other/Caucasian | Participants | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized: Not Hispanic or Latino | Participants | 18 | 18 | 17 | 18 | 71 |
6. Primary Endpoint
The registry lists the primary outcome as Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ), measured over From Baseline (Day 1 predose) at predefined time points (up to Day 140).
| Element | Registry entry |
|---|---|
| Result type | Geometric Mean |
| Measure of spread | Geometric Coefficient of Variation |
| Unit | days*micrograms/milliliter (days*ug/mL) |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint is the area under the plasma concentration-time curve from time zero to infinity for a single dose of bimekizumab. In this study, time zero is defined as the Day 1 predose point, and blood sampling was scheduled at predefined time points up to Day 140. AUC summarizes overall drug exposure over time rather than describing concentration at just one sampling point. The record reports the endpoint as a geometric mean, with geometric coefficient of variation as its measure of dispersion.
In general, pharmacokinetic exposure measures are used in bioequivalence studies to compare how much drug reaches the circulation and how exposure unfolds after different formulations or administration presentations. AUC is relevant because the question concerns whether the 2 mL presentation and the two 1 mL injections result in comparable overall exposure. The endpoint does not by itself describe every aspect of the concentration profile. The registry also lists maximum concentration and its timing among other outcomes, but the primary endpoint addressed on this page is AUC.
The primary analysis population was the pharmacokinetic per-protocol set. According to the record, this set consisted of participants from the full analysis set who had no important protocol deviations affecting pharmacokinetic variables and had sufficient samples to determine at least one pharmacokinetic parameter. The exact handling of incomplete or unusable samples beyond that definition is not reported in the registry record. The endpoint’s definition is stated, but assay details and the model used to estimate the geometric means are not reported in the registry record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The posted AUC summaries show geometric means of 1665.0 for the safety-syringe 2 mL test group and 1610.0 for its two 1 mL reference group. For the auto-injector, the corresponding summaries are 1560.0 for the 2 mL test group and 1357.0 for the two 1 mL reference group. The arm summaries also report geometric coefficients of variation of 34.2 and 31.3 for the safety-syringe pair, and 19.1 and 35.5 for the auto-injector pair. These are summaries of the observed pharmacokinetic data, not by themselves the complete bioequivalence assessment.
The registry’s sponsor-reported comparison for the safety-syringe presentations is a geometric mean ratio of 103.4, with a 90% confidence interval from 86.4 to 123.8. For the auto-injector presentations, the reported ratio is 115.0, with a 90% confidence interval from 97.9 to 135.0. These intervals convey uncertainty around the estimated ratios: values nearer the estimate are generally more compatible with the observed data than values farther away, while the interval also shows a range of values consistent with the analysis under its assumptions. They are not a probability statement that the true ratio lies within the interval.
Whether either comparison qualifies as bioequivalent depends on the acceptance margins and decision rules chosen for the study. Those criteria are not reported in the registry record. It would therefore be inappropriate to infer a pass or fail from the ratios and intervals alone, even though the record labels these as equivalence analyses. The two device-specific comparisons should also be read separately; their estimates and uncertainty differ, and they do not establish a direct comparative effect between devices.
The reported results concern pharmacokinetic exposure in healthy participants after a single dose. They do not answer questions about repeated administration, clinical outcomes, or populations with a health condition. Nor do the arm summaries alone show why an interval has its particular width. Precision depends on features including variability and the number of analyzable participants, and the posted arm counts are limited. The record does not report a detailed rationale for the sample size or a prespecified analysis plan sufficient to assess all modeling choices.
The safety summaries are separate from the AUC findings. The registry reports no serious adverse events in any of the four groups and reports other treatment-emergent adverse events in each group. These counts should not be taken as evidence about comparative safety beyond the study and follow-up recorded. Overall, the posted data give estimates of exposure and uncertainty for two specific presentation comparisons; the information available does not establish how those estimates were judged against the trial’s intended equivalence criteria.
9. Statistical Methods Explained
The analysis is best understood as two device-specific bioequivalence comparisons. In the safety-syringe comparison, the 2 mL test presentation is compared with the two 1 mL reference injections. In the auto-injector comparison, the 2 mL test presentation is compared with its two 1 mL reference injections. Keeping the comparisons within device type makes the intended question easier to interpret: whether changing the volume presentation is associated with a different AUC under each delivery presentation. The record does not report a direct statistical comparison of the safety syringe against the auto-injector.
What does a geometric mean summarize?
The primary endpoint is reported as a geometric mean. In general, geometric means are useful for measurements such as pharmacokinetic exposure that can be right-skewed, where a small number of relatively large values can influence an arithmetic mean. A geometric mean is based on the logarithms of the observations and then expressed back on the original scale. The registry record does not state the exact transformation or estimation model used for the posted values, so this is a general explanation rather than a description of a confirmed analysis procedure.
The record reports geometric coefficients of variation as the dispersion measure. In general, a coefficient of variation expresses spread relative to the scale of the data, which can make variability easier to compare across groups with different means. A geometric coefficient of variation is associated with log-scale variability. Greater variability generally means less precision for a group summary or comparison, all else being equal. The posted dispersion values do not, on their own, determine the confidence interval for the ratio; the analysis model and available observations also matter.
How should the ratio and interval be read?
A geometric mean ratio compares the geometric mean exposure in the test group with that in the reference group. The registry reports values of 103.4 for the safety-syringe comparison and 115.0 for the auto-injector comparison. Their 90% confidence intervals are 86.4 to 123.8 and 97.9 to 135.0, respectively. In general, the point estimate gives the central estimate from the analysis, while the confidence interval expresses its statistical uncertainty under the analysis assumptions. A wider interval indicates less precision than a narrower interval, although the interval’s width should be interpreted in context rather than as a measure of clinical importance.
Bioequivalence is not established merely by inspecting whether a point estimate appears close to a reference value. In general, a bioequivalence decision compares an interval with prespecified acceptance bounds. The registry record does not report those bounds or the precise decision rule, so this page cannot determine from the posted numbers alone whether the sponsor’s formal criterion was met. The equivalence label in the analysis record identifies the type of comparison, but does not replace the missing criteria.
Why does the analysis population matter?
The registry defines the pharmacokinetic per-protocol set as a subset of the full analysis set, excluding participants with important protocol deviations affecting pharmacokinetic variables and requiring enough samples to estimate at least one pharmacokinetic parameter. Such a definition is relevant because bioequivalence depends on usable exposure measurements and adherence to procedures affecting those measurements. In general, excluding participants can affect both the estimate and its precision. A transparent report would ideally show how many participants were randomized, treated, included in each analysis, and excluded with reasons. That complete accounting is not reported in the registry record.
What cannot be reconstructed from the record?
The record does not state the statistical model, transformations, variance assumptions, handling of values below quantification limits, missing-data procedures, or the precise derivation of the interval estimates. It does not report prespecified equivalence margins or any multiplicity strategy for the two comparisons. It is therefore not possible to reproduce the sponsor’s analysis from the posted summary statistics alone or to verify all of its assumptions. General statistical principles help explain the reported measures, but they should not be mistaken for methods confirmed in this study.
The sample-size illustrations elsewhere on the page are planning scenarios based on the observed effect and specified assumptions. In general, such scenarios can show how design choices affect the number of participants needed to target a chosen level of power under those assumptions. They are not evidence of the study’s original planning process, and they are not observed power. The registry record does not report the original sample-size justification. No inference about that justification or about interim analyses can be made from the information recorded.
10. Analyses Reported by the Sponsor
| Method | Estimate | 95% CI | P-value |
|---|---|---|---|
| not stated | Geometric Mean Ratio 103.4 | 86.4 to 123.8 | not reported |
| not stated | Geometric Mean Ratio 115.0 | 97.9 to 135.0 | not reported |
The registry posts the sponsor’s own geometric mean ratio analyses: 103.4 with a 90% confidence interval from 86.4 to 123.8 for the safety-syringe comparison, and 115.0 with a 90% confidence interval from 97.9 to 135.0 for the auto-injector comparison. These are the relevant reported comparative estimates for the primary AUC endpoint. The registry does not give a p-value for either comparison.
No discrepancy between a sponsor analysis and a recalculated comparison is identified in the registry record. The posted arm summaries include geometric means and geometric coefficients of variation, but those summaries alone are not a substitute for the sponsor’s model-based comparison. A simple recalculation from summaries, if shown elsewhere on the page, should be treated as an unadjusted check and not as a replacement for the sponsor’s analysis. In the absence of a reported discrepancy, the sponsor’s posted analysis is the appropriate primary account of the trial’s comparative estimates.
The registry does not report the model details, equivalence margins, or decision rule needed to independently verify the formal bioequivalence conclusion. Consequently, the reported ratio and interval can be described, but the record does not support a definitive interpretation against the study’s intended acceptance criteria.
11. Multiplicity, Missing Data and Analysis Populations
The primary endpoint is AUC, and the registry posts two related comparisons: one for the safety-syringe presentations and one for the auto-injector presentations. It also lists secondary outcomes involving treatment-emergent adverse events, serious adverse events, apparent terminal half-life, and the timing of maximum observed concentration. The record lists seven outcome measures and six analyses. It does not describe whether the two primary comparisons were treated as co-primary, whether one was primary and the other supportive, or how the wider set of outcomes was prioritized.
Multiplicity concerns arise when several hypotheses or outcomes are assessed. In general, making multiple statistical decisions can increase the chance of at least one result appearing notable by chance, depending on the testing strategy and dependence among tests. Bioequivalence assessments may use a prespecified set of criteria rather than a conventional test for difference, but the margin and any multiplicity handling still matter for interpretation. Neither the acceptance bounds nor the strategy for handling the two comparisons and other outcomes is reported in the registry record. The posted confidence intervals should therefore be read as reported, without assuming an adjustment that is not documented.
Missing-data handling is also not described in detail. The primary analysis population required sufficient samples to determine at least one pharmacokinetic parameter and excluded important protocol deviations affecting pharmacokinetic variables. The record does not give a participant flow by arm, reasons for missing measurements, rules for incomplete sampling, or sensitivity analyses addressing exclusions. It also does not describe the handling of missing safety observations.
The analysis population distinction matters: 71 participants were enrolled, while the posted AUC arm summaries list 18, 18, 17, and 18 participants. The record does not provide enough detail to fully reconcile enrollment with every analysis population or to determine whether all randomized participants received the assigned presentation. These omissions limit independent assessment of the robustness and completeness of the posted results.
12. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Bimekizumab-SS-2mL (Test 1) | 0 | 18 | 0.0% |
| Bimekizumab-SS-2x1mL (Reference 1) | 0 | 18 | 0.0% |
| Bimekizumab-AI-2mL (Test 2) | 0 | 17 | 0.0% |
| Bimekizumab-AI-2x1mL (Reference 2) | 0 | 18 | 0.0% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Bimekizumab-SS-2mL (Test 1) | 0 of 18 |
| Bimekizumab-SS-2x1mL (Reference 1) | 0 of 18 |
| Bimekizumab-AI-2mL (Test 2) | 0 of 17 |
| Bimekizumab-AI-2x1mL (Reference 2) | 0 of 18 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Bimekizumab-SS-2mL (Test 1) | 12 of 18 |
| Bimekizumab-SS-2x1mL (Reference 1) | 8 of 18 |
| Bimekizumab-AI-2mL (Test 2) | 12 of 17 |
| Bimekizumab-AI-2x1mL (Reference 2) | 7 of 18 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|---|
| Headache | Nervous system disorders | 4 of 18 | 4 of 18 | 3 of 17 | 1 of 18 |
| Back pain | Musculoskeletal and connective tissue disorders | 1 of 18 | 2 of 18 | 4 of 17 | 0 of 18 |
| Injection site haematoma | General disorders | 1 of 18 | 0 of 18 | 0 of 17 | 3 of 18 |
| Dry mouth | Gastrointestinal disorders | 0 of 18 | 1 of 18 | 2 of 17 | 0 of 18 |
| Oral herpes | Infections and infestations | 2 of 18 | 1 of 18 | 0 of 17 | 0 of 18 |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 0 of 18 | 0 of 18 | 1 of 17 | 2 of 18 |
| Diarrhoea | Gastrointestinal disorders | 1 of 18 | 0 of 18 | 0 of 17 | 1 of 18 |
| Nausea | Gastrointestinal disorders | 0 of 18 | 2 of 18 | 0 of 17 | 0 of 18 |
| Vomiting | Gastrointestinal disorders | 0 of 18 | 1 of 18 | 0 of 17 | 1 of 18 |
| Injection site pain | General disorders | 1 of 18 | 0 of 18 | 1 of 17 | 0 of 18 |
The registry reports zero serious adverse events among the participants at risk in each group: 18 in the safety-syringe 2 mL group, 18 in its two 1 mL reference group, 17 in the auto-injector 2 mL group, and 18 in its two 1 mL reference group. It also reports zero deaths in each group. These are event counts over the safety follow-up described in the outcome title; the exact follow-up duration is not reported in the registry record.
The record reports at least one treatment-emergent adverse event in 12 participants in the safety-syringe 2 mL group, 8 in the safety-syringe reference group, 12 in the auto-injector 2 mL group, and 7 in the auto-injector reference group. These counts are not the primary endpoint and should not be conflated with serious events. The registry lists the percentage of participants with at least one event as a secondary outcome, but the posted count data are sufficient only to describe the number affected in each group.
Zero observed serious events does not establish that serious events cannot occur, and the event counts do not support broad conclusions about safety outside this study. This was a single-dose study in healthy participants, and its group sizes were limited. The registry does not provide serious-event terms, since none are listed, or a detailed account of event severity, timing, or relatedness. These results should be read as the safety observations recorded for this study, not as a general safety comparison.
13. What the Result Does, and Does Not, Mean
This study addresses a specific pharmacokinetic question: whether bimekizumab exposure, measured by AUC, differs between a 2 mL presentation and two 1 mL injections when using the safety syringe or auto-injector. The posted estimates and confidence intervals describe the observed data for those comparisons. They provide more information than the point estimates alone because they show the uncertainty around each ratio.
The results do not, on their own, establish a formal bioequivalence conclusion. Such a conclusion depends on the acceptance margins and statistical decision rule set for the study. Those details are not reported in the registry record. The analysis entries are labeled equivalence, but the record does not show the criteria against which the reported intervals were judged. Readers should not infer that a criterion was or was not met solely from the numbers.
The results also do not establish that the two delivery devices are equivalent to each other. Each posted comparison is between the 2 mL and two 1 mL presentations within one device type. They do not answer whether a safety syringe and an auto-injector produce the same exposure, and no direct statistical comparison between devices is reported.
The findings are confined to a single-dose pharmacokinetic study in healthy participants. They do not address repeated dosing, clinical outcomes, or participants with a health condition. The study’s status is listed as terminated, but the reason is not reported in the registry record, so no explanation should be inferred. The safety data are descriptive and are not sufficient to characterize uncommon or longer-term risks.
In short, the posted results document two exposure estimates and their uncertainty, alongside limited safety counts. They help describe the study’s recorded pharmacokinetic findings, while important information about the formal equivalence criteria, detailed analysis methods, and participant flow remains unavailable in the registry record.
14. Why This Trial Matters Statistically
Bioequivalence questions often concern changes in formulation, volume, or delivery presentation rather than comparisons between different active drugs. This study is statistically interesting because it separates two presentation-specific questions: a safety-syringe comparison and an auto-injector comparison. Keeping those comparisons distinct avoids treating the device as though it were the only difference under investigation.
The AUC endpoint is a measure of overall plasma exposure, and the registry reports both geometric mean ratios and confidence intervals. This gives readers a way to consider the estimate and its precision together. It also illustrates why reporting only group summaries is not enough for a formal equivalence assessment: the interpretation depends on the comparison interval and the predefined bounds used to judge it. Those bounds are not reported in the registry record, leaving a key part of the statistical decision unavailable.
The study also highlights the importance of clearly describing analysis populations. The primary endpoint used a pharmacokinetic per-protocol set with criteria tied to protocol deviations and sample availability. That definition helps explain who contributed to the primary analysis, but the registry does not provide a complete participant flow. Without that accounting, readers cannot fully assess how the analysis set relates to all enrolled participants.
Finally, the record distinguishes pharmacokinetic outcomes from safety outcomes. It reports no serious adverse events in the groups, while also reporting participants with other treatment-emergent adverse events. These measures answer different questions and should not be combined into a single judgment. The value of this record lies in showing the study’s design and posted summaries while also making visible how missing methods and decision criteria constrain independent statistical interpretation.
15. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
Several limitations specific to this trial affect interpretation. The study enrolled healthy participants and evaluated a single dose, so the posted AUC estimates do not describe exposure under repeated dosing or in other populations. The registry labels the study terminated, but does not report why it was terminated or how that status related to the conduct or reporting of the study.
The primary results are presented as geometric means, geometric coefficients of variation, and sponsor-reported ratios with 90% confidence intervals. However, the registry does not report the equivalence margins or detailed decision rule. Without those criteria, the formal equivalence interpretation cannot be independently established from the posted estimates. The statistical model, handling of missing samples, transformations, and other analysis details are also not reported in the registry record.
Although the primary analysis population is defined, participant flow and exclusions by arm are not fully described. The record does not show how every enrolled or randomized participant was accounted for in the primary analysis or safety follow-up. That makes it harder to assess the potential impact of exclusions and missing observations.
The posted safety data include counts for serious events, other treatment-emergent events, and deaths, but the registry does not report event severity, timing, or relatedness in the information. The study’s limited size and single-dose setting also restrict what can be learned about less common events. Finally, the registry does not state the sample-size justification, interim-analysis plans, or multiplicity strategy. Those omissions limit assessment of the study’s planning and of how the two primary comparisons and secondary outcomes were interpreted.
16. Related Tutorials
17. Related Statistical Calculators
18. Sources
- ClinicalTrials.gov: A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants — NCT04255862.
- Registry record last updated 2025-04-10; status last verified 2025-03.
- Results first posted 2025-04-10.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
19. Record Summary
This phase 1, randomized, open-label, single-center, parallel-group, single-dose study evaluated bimekizumab in healthy participants. It compared a 2 mL presentation with two 1 mL injections separately for the safety syringe and auto-injector. The registry lists 71 participants enrolled and marks the study as terminated.
The primary endpoint was AUC from time zero to infinity, with sampling scheduled up to Day 140. The sponsor-reported geometric mean ratios were 103.4, with a 90% confidence interval from 86.4 to 123.8, for the safety-syringe comparison, and 115.0, with a 90% confidence interval from 97.9 to 135.0, for the auto-injector comparison. The equivalence margins and detailed analysis methods are not reported in the registry record.
No serious adverse events or deaths were reported in the four groups. Other treatment-emergent adverse events were reported in each group. These findings describe the posted study results but do not support conclusions beyond this study’s population, dosing, and follow-up.